Cidara Therapeutics Inc (CDTX)
14.37
-0.11
(-0.76%)
USD |
NASDAQ |
Nov 15, 16:00
14.11
-0.26
(-1.81%)
After-Hours: 20:00
Cidara Therapeutics Research and Development Expense (TTM): 70.46M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 70.46M |
| June 30, 2024 | 68.42M |
| March 31, 2024 | 70.42M |
| December 31, 2023 | 77.69M |
| September 30, 2023 | 59.86M |
| June 30, 2023 | 69.51M |
| March 31, 2023 | 76.11M |
| December 31, 2022 | 77.40M |
| September 30, 2022 | 74.48M |
| June 30, 2022 | 74.94M |
| March 31, 2022 | 77.40M |
| December 31, 2021 | 73.09M |
| September 30, 2021 | 75.20M |
| June 30, 2021 | 70.96M |
| March 31, 2021 | 70.87M |
| December 31, 2020 | 68.02M |
| September 30, 2020 | 58.38M |
| June 30, 2020 | 53.62M |
| March 31, 2020 | 46.73M |
| December 31, 2019 | 46.40M |
| Date | Value |
|---|---|
| September 30, 2019 | 47.96M |
| June 30, 2019 | 47.74M |
| March 31, 2019 | 48.61M |
| December 31, 2018 | 49.14M |
| September 30, 2018 | 46.33M |
| June 30, 2018 | 44.21M |
| March 31, 2018 | 45.78M |
| December 31, 2017 | 42.82M |
| September 30, 2017 | 43.90M |
| June 30, 2017 | 43.47M |
| March 31, 2017 | 38.75M |
| December 31, 2016 | 35.70M |
| September 30, 2016 | 31.95M |
| June 30, 2016 | 29.99M |
| March 31, 2016 | 25.73M |
| December 31, 2015 | 23.48M |
| September 30, 2015 | 19.38M |
| June 30, 2015 | 14.61M |
| March 31, 2015 | 11.37M |
| December 31, 2014 | 6.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
46.40M
Minimum
Dec 2019
77.69M
Maximum
Dec 2023
68.00M
Average
70.66M
Median
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Arbutus Biopharma Corp | 62.79M |
| GlycoMimetics Inc | 22.89M |
| FibroGen Inc | 185.40M |
| Cue Biopharma Inc | 40.49M |